Maine lawmaker wants insurance to cover PFAS blood tests for exposed communities
Though almost everyone in the U.S. likely has some level of PFAS in their blood, testing can show the specific level a person has. (Photo by TEK IMAGE/SCIENCE PHOTO LIBRARY via Getty Images)
Adam Nordell has been undergoing a new treatment to reduce the high levels of forever chemicals in his blood; the same toxins that forced him and his wife to lose their Unity farm to contamination.
Nordell said he and his doctors know the treatment is working because blood tests show his levels of perfluoroalkyl and polyfluoroalkyl substances, also known as PFAS, are decreasing faster than they would have without the medication.
Insurance isn't covering the cost of the medication and Nordell said he's had some coverage for his blood tests — which he described as 'a critical component of preventative care for Maine's PFAS-exposed communities.'
Farmers like Nordell who worked on acreage historically treated with wastewater sludge are not the only populations exposed to the chemicals, which have been linked to health concerns including cancer, liver damage, pregnancy complications, increased cholesterol levels and more. Workplace exposure is high for firefighters, chemical manufacturers and ski wax technicians while communities exposed to spills also face risk.
Struggling to adapt
Nordell, who now works as a campaign manager for Defend Our Health, shared his story with the Legislature's Health Coverage, Insurance and Financial Services Committee during a public hearing for LD 582, which would require health insurance carriers to cover blood tests for PFAS when they are deemed medically necessary. The proposal would apply to health plans issued or renewed after Jan. 1, 2026.
The bill is sponsored by Sen. Stacy Brenner (D-Cumberland), who introduced a similar measure in the 131st Legislature that passed in the House of Representatives but died when the session adjourned without approval from the Senate.
Awareness of the toxic chemicals has increased as the state has worked to remediate agricultural land contaminated by the state-sanctioned spreading of sludge. Meanwhile, a spill of 1,450 gallons of PFAS-laden firefighting foam concentrate in Brunswick last summer also highlighted the dangers posed to communities near airports and fire stations.
Though almost everyone in the U.S. likely has some level of PFAS in their blood, testing can show the specific level a person has. However, blood tests for PFAS can not identify a specific health problem or treatment information, according to the U.S. Centers for Disease Control and Prevention.
Blood tests not only help monitor the health of people exposed to PFAS who are at risk of developing complications but can also help identify the sources of exposure, said Abby Fleisch, a Portland-based pediatric endocrinologist who leads research on the health effects of PFAS. Fleisch testified in favor of the bill on behalf of the Maine Chapter of the American Academy of Pediatrics.
Arguing that PFAS exposure testing is generally investigatory rather than medically necessary, the Maine Association of Health Plans opposed the bill because it sees the proposal as a public health screening program that will increase the cost of health insurance premiums.
'Maine's insurance code is not the place to establish or fund public health initiatives,' said Executive Director Dan Demeritt in his testimony.
Anthem Blue Cross Blue Shield also submitted testimony against the bill.
Stacy Bergendahl, a senior staff attorney, testified on behalf of the Maine Bureau of Insurance neither for nor against the bill. She explained that mandated benefits increase costs for individuals and businesses responsible for paying health insurance premiums. Though this particular mandate wouldn't add a significant cost, she said the cumulative cost of all state-mandated benefits can have a substantial impact.
If the committee moves forward with the bill, the bureau recommends changing the effective date to 2027 to give insurance carriers time to implement any required price changes that would result.
Bergendahl also explained that the state would be required under the Affordable Care Act to pay the cost of the mandated benefits for health plans sold through the health insurance exchange, CoverMe.gov. Brenner argued that the PFAS blood test could qualify as a preventative measure, which the state can get reimbursed, but the bureau said the test is not currently included on the list of preventative services.
PFAS blood tests generally cost between $400 and $600, according to testimony from providers. However, Brenner said that costs are coming down as the tests become more accessible.
Given that PFAS exist in a multitude of products people use every day, a member of the committee asked Brenner if she thinks coverage for the blood tests could grow beyond the group of people identified as being at higher-risk. Brenner said she would be surprised if that happened because it wouldn't be a useful expenditure of health care dollars given the likely baseline exposure in most Americans.
'We want to support the most impacted communities so that they're safe and the associated healthcare impacts are covered,' Brenner said.
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Dove Men+Care Encourages Canadian Dads to Celebrate ‘My Most Important Role' on LinkedIn
TORONTO--(BUSINESS WIRE)--To mark Father's Day, Dove Men+Care invites Canadian Dads and father figures to update their LinkedIn profiles with one of their most meaningful life roles: 'Dad.' Rolling out across Canada, the campaign encourages fathers to recognize and celebrate fatherhood as a full-time role and claim space for it on a platform traditionally reserved for professional milestones. As part of the campaign, Canadian Dads are encouraged to use LinkedIn's 'Add position' feature to reflect their role as a father and join a growing movement of men reshaping the traditional definition of masculinity, identity, and care. Making fatherhood LinkedIn-official, Dove Men+Care sparks a broader conversation that urges men to treat personal milestones with the same importance and visibility as professional ones. 'Too often, men proudly share promotions, but rarely the presence and care they bring at home,' said Divya Singh, General Manager, Personal Care, Unilever Canada. 'With this campaign, we are redefining success to include care and celebrate the powerful role fathers and father figures play beyond the workplace.' To kickstart the movement, Dove Men+Care partnered with Founder/CEO Ross Simmonds, Sports Commentator Donnovan Bennett, Celebrity Chef and TV host Dave Rocco, Innovation Strategist Shawn Kanungo. Each thought leader, known in Canada for their professional achievements, are sharing their personal fatherhood stories alongside custom visuals designed by Toronto-based illustrator Mateusz Napieralski. Canadians are encouraged to download and re-share these custom illustrations along with their own fatherhood update and journey. "When men see fatherhood as a vital part of who they are, it positively shapes their mental health and emotional well-being," said Dr. Andrew Howlett, a Toronto-based Child and Family Psychiatrist, and co-founder of the Fathers' Mental Health Network. "By valuing and supporting active fatherhood, we help dads feel recognized and empowered - building resilient families and healthier communities." As a long-time partner of Dove Men+Care, Dad Central, a national organization that provides research, programming, resources, and a community to support father involvement, is helping amplify the campaign through its extensive community network. The group is also contributing expert insight on the cultural importance of active fatherhood and its long-term impact on society. The campaign runs nationally in the lead-up to Father's Day, encouraging Dads across Canada to take part on LinkedIn. To learn more about Dove Men+Care, visit To find out more about Dad Central visit: About Dove Men+Care Dove Men+Care is the first range of products from Dove developed specially for men. Manufactured by Unilever, the line includes the #1 dermatologist recommended male bar and body wash brand. Launched in 2010, the Dove Men+Care portfolio includes bars, body washes, anti-perspirant/deodorants, and hair care. Dove Men+Care is available nationwide in food, drug, and mass outlet stores. About Unilever Unilever is one of the world's leading suppliers of Beauty & Wellbeing, Personal Care, Home Care, Foods and Ice Cream products, with sales in over 190 countries and products used by 3.4 billion people every day. We have 128,000 employees and generated sales of €60.8 billion in 2024. For more information about Unilever and our brands, please visit About Unilever in North America Unilever is one of the world's leading suppliers of Beauty & Wellbeing, Personal Care, Home Care, Foods and Ice Cream products, with sales in over 190 countries and products used by 3.4 billion people every day. We have 128,000 employees and generated sales of €60.8 billion in 2024. Our leading brands in North America include Dove, Hellmann's, Vaseline, Degree, Axe, TRESemmé, Knorr, Magnum, Ben & Jerry's, Nutrafol, Liquid I.V., Paula's Choice, and Dermalogica. For more information on Unilever U.S. and its brands visit: For more information on Unilever Canada and its brands visit: About Unilever in Canada Unilever is one of the world's leading suppliers of Beauty & Wellbeing, Personal Care, Home Care, Foods and Ice Cream products, with sales in over 190 countries and products used by 3.4 billion people every day. We have 128,000 employees and generated sales of €60.8 billion in 2024. Our leading brands in Canada include Dove, Vaseline, Degree, Axe, SheaMoisture, TRESemmé, Knorr, Hellmann's, Breyers, Magnum, Ben & Jerry's, Liquid I.V., and OLLY. For more information on Unilever Canada and visit: or About Dad Central Dad Central is a national non-profit organization dedicated to supporting and promoting responsible father involvement in Canada. Through evidence-based research, resources, and community programming, Dad Central helps fathers, families, and organizations recognize and strengthen the important role dads play in child development and family well-being. With over two decades of experience, Dad Central works to ensure every child has the opportunity to benefit from an involved and caring father.
Yahoo
2 hours ago
- Yahoo
ReproTech LLC ("ReproTech") has made a significant growth investment in Matcher Technologies Ltd ("Matcher") to support its expansion across the fertility sector
DOVER, Del., June 9, 2025 /PRNewswire/ -- ReproTech, a leading provider of reproductive cryostorage and cryostorage technology solutions, is pleased to announce a significant investment in Matcher Technologies Ltd, a recognized innovator in the fertility industry known for its flagship electronic witnessing product, IMT Matcher. This strategic investment strengthens ReproTech's leadership in cryostorage by enhancing its existing traceability solutions. The integration of Matcher's expertise and technology with ReproTech's existing suite of cryostorage and safety focused products marks a major step towards the first comprehensive platform for patients and clinics to digitally document every step of the IVF process while providing the safest storage solutions on the market. "We are thrilled to partner with Matcher to continue our combined journey of providing the highest quality, safest and most compliant products for our clinic partners," said Brad Senstra, ReproTech CEO. "Their team, technology, mission and values align perfectly with our commitment to exceptional service, advanced technologies, and stringent compliance standards." Matcher Technologies Ltd, founded in 2005, has built a strong reputation for the capability and quality of its product, continual innovation, and excellent customer service. Following the investment, Matcher's operations will continue from its U.K. headquarters uninterrupted for end users and the existing distributor network. "ReproTech's reputation as a trusted storage solutions partner—with 35 years of experience—and their dedication to advancing traceability in fertility care make them an ideal partner," said George Heywood, CEO of Matcher Technologies Ltd. "Together, we can drive innovation and enhance our service offerings in both domestic and international markets." ReproTech was advised by Shoosmiths LLP, BDO LLP, and Armstrong Teasdale LLP. Matcher Technologies Ltd was supported by Clearwater International, Brabners LLP, and Claritas Tax. For more information, visit the Reprotech or IMT Matcher website or contact: Media Contact:Joy ZardeckiSVP Business Development & Administrationjzardecki@ About ReproTech ReproTech is a Delaware-based provider of cryostorage technology solutions, off-site storage and logistics services. The company partners with fertility clinics, hospital systems, donor banks, and andrology laboratories across North America to offer secure, state-of-the-art storage for sperm, oocytes, embryos, stem cells, oncofertility specific tissues, and other reproductive tissues - ensuring patients have future options for family formation. ReproTech distinguishes itself through exceptional service, advanced technologies, and stringent compliance standards. Learn more at About Matcher Technologies Ltd Matcher Technologies Ltd. is a UK based, global leader in fertility technology, renowned for developing IMT Matcher - the world's first electronic witnessing system - over 20 years ago. Over the past two decades, the company has played a pivotal role in shaping industry standards and educating the market. Built on insights from hundreds of fertility center customers worldwide, IMT Matcher has become the highest quality witnessing and traceability system of choice for clinics across the globe. With a deep commitment to innovation, Matcher has continuously invested in product development, driven by a highly skilled, multi-disciplinary, global team. The company's commitment to quality is underscored by longstanding relationships with global players and a trusted reputation for delivering excellent customer service in pursuit of protecting patients, fertility centers and donor banks from the risks of error in IVF. Learn more at View original content to download multimedia: SOURCE ReproTech, LLC Sign in to access your portfolio


Business Wire
3 hours ago
- Business Wire
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders
AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V. ('Avanzanite'), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe' Share 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe,' said Adam Plich, Founder and CEO of Avanzanite. 'We provide biotech partners with a capital-efficient path to sustainable patient access – without the burden of building a costly local infrastructure. We look forward to working with Agios to help bring PYRUKYND® to patients across Europe, further advancing our efforts to set a new benchmark for biotech commercial and distribution partnerships in the region. This is just the beginning.' PYRUKYND®, a first-in-class, oral, pyruvate kinase (PK) activator, is approved by the European Commission and the UK's Medicines and Healthcare products Regulatory Agency for the treatment of adult patients with PK deficiency. PK deficiency is an ultra-rare, inherited condition that causes premature red blood cell breakdown, leading to chronic anemia, serious complications, and reduced quality of life. Until recently, there were no approved treatments. Agios also has a robust mid- and late-stage pipeline, with clinical programs focused on other rare diseases, including thalassemia and sickle cell disease. The partnership also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand into 32 European countries, including new territories of Italy, France, the UK, Romania, and Spain. 'Avanzanite goes truly pan-European,' concluded Plich. 'And as we expand across the continent, our promise stays the same – making sure no patient is left behind.' About Avanzanite Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the company partners with biotech innovators to unlock the full commercial value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe's complex landscape like master chess players – ensuring no patient is left behind. Learn more at